



NOXXON PHARMA ANNOUNCES NEW PRECLINICAL DATA SHOWING SYNERGY OF LEAD COMPOUND NOX-A12 WITH NATURAL KILLER (NK) CELL MEDIATED THERAPIES

THESE DATA WILL BE PRESENTED AT THE AMERICAN SOCIETY OF HEMATOLOGY (ASH) CONFERENCE

Berlin, Germany, December 5, 2016, NOXXON Pharma N.V. (Alternext Paris: ALNOX) a clinical-stage biopharmaceutical company primarily focused on cancer treatment, announces that it presented data at the ASH conference in San Diego, California studying the role of CXCL12 inhibition by NOX-A12 (olaptosed pegol) on Natural Killer (NK) cells in tumor stroma spheroids, a preclinical model that mimics the complexity of the tumor microenvironment. These studies showed that NOX-A12 synergizes with NK cell mediated antibody-dependent cellular cytotoxicity (ADCC). Further studies of NOX-A12 with agents working through NK cell-based therapies are warranted.

Poster Title: CXCL12 Inhibition by NOX-A12 (Olaptesed Pegol) Synergizes With the ADCC Activity of CD20 Antibodies by Increasing NK Cell Infiltration in a 3D Lymphoma Model

Authors: Dirk Zboralski, Anna Kruschinski, Dirk Eulberg and Axel Vater

Location & time: 58th ASH Annual Meeting, San Diego, CA, USA, Abstract #3021, Session 625 Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Poster II. Sunday, December 4, 2016 from 18:00 – 20:00

The poster may be downloaded from the company's website:

<http://www.noxxon.com/downloads/poster/ash2016.pdf>

NOX-A12, which inhibits the key tumor microenvironment chemokine CXCL12, may be a key partner for a wide range of IO (immuno-oncology) agents. NOXXON has generated promising pre-clinical and clinical data, including recent animal data showing synergy with a checkpoint inhibitor as well as recent phase 2a trials in multiple myeloma and a second hematological cancer that showed a safety profile that supports further development and first signs of efficacy. The Company believes that additional clinical trials are warranted to investigate combinations of NOX-A12 multiple classes of IO agents including those acting on or through T-cells and NK cells.

For more information, please contact:

NOXXON Pharma N.V.

Aram Mangasarian, Ph.D., Chief Executive Officer

Tel. +49 (0) 30 726 2470

amangasarian@noxxon.com

NewCap

Florent Alba

Tel. +33 (0) 1 44 71 98 55

falba@newcap.fr

About NOXXON

NOXXON Pharma N.V. is a clinical-stage biopharmaceutical company focused on cancer treatment. NOXXON's goal is to significantly enhance the effectiveness of cancer treatments including immuno-oncology approaches (such as immune checkpoint inhibitors) and current standards of care (such as chemotherapy and radiotherapy). NOXXON's Spiegelmer® platform has generated a proprietary pipeline of clinical-stage product candidates including its lead cancer drug candidate NOX-A12. NOXXON is supported by a strong group of leading international investors, including TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, DEWB, NGN and Seventure. NOXXON has its statutory seat in Amsterdam, The Netherlands and its office in Berlin, Germany. Further information can be found at: www.noxxon.com